D. E. Shaw & Co., Inc. Vaxcyte, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 775,653 shares of PCVX stock, worth $64.7 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

775,653

Previous 423,498 83.15%

Holding current value

$64.7 Million

Previous $48.4 Million 31.32%

% of portfolio

0.05%

Previous 0.05%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$80.97 - $117.93 $28.5 Million - $41.5 Million	352,155 Added 83.15%	775,653 $63.5 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $13.6 Million - $22.6 Million	193,291 Added 83.96%	423,498 $48.4 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $8.23 Million - $10.8 Million	-137,042 Reduced 37.32%	230,207 $17.4 Million
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $4.25 Million - $5.76 Million	-71,062 Reduced 16.21%	367,249 $25.1 Million
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $4.54 Million - $6.35 Million	-100,073 Reduced 18.59%	438,311 $27.5 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $12.6 Million - $14.6 Million	-274,528 Reduced 33.77%	538,384 $27.4 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $624,053 - $973,530	18,005 Added 2.27%	812,912 $40.6 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $6.43 Million - $8.37 Million	-177,414 Reduced 18.25%	794,907 $29.8 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $20 Million - $46.6 Million	972,321 New	972,321 $46.6 Million

Others Institutions Holding PCVX

# of Institutions

346

Shares Held

130M

Call Options Held

534K

Put Options Held

248K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.94B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account